Solos acquires cancer-detection products from Lifeline for $4 million

By Elaine Rigoli

Tampa, Fla., June 15 - Lifeline Biotechnologies, Inc. has agreed to sell its early cancer-detection product line to Solos Endoscopy, Inc. for $4 million in restricted shares of Solos.

Solos said it will obtain medical assets from Lifeline Biotechnologies, which will include the MastaScope, First Warning System, OvaScope and the intellectual properties of those products.

Lifeline will also receive a royalty, once sales of the MastaScope, First Warning System and OvaScope exceed $4 million, according to a news release.

Lifeline recently announced that the company is actively pursuing acquisition and merger candidates in the medical, nutraceutical and energy industries.

Lifeline is a medical technologies company located in Reno, Nev.

Solos is a health care technology company located in Boston.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.